Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools ACC

ACC

Programs, trials, and reported response and survival for adenoid cystic carcinoma.

Data as of 11.07.2026

ACC pipeline

Drugs

Every adenoid cystic carcinoma program in this file, grouped by class. Open a drug for its studies and the sources behind each figure.

ClassNone selected
Route

A route is listed here when at least one program uses it. The full list is on Methods. Unknown means the source did not name a route.

All programs shown

23 of 23 programs shown

B7-H4-directed ADC 2 drugs

CXCR1/2 inhibitor 1 drug

EGFR x MET bispecific antibody 1 drug

  • AmivantamabTrisha Wise-Draper (investigator)Phase 2intravenous1 studyEGFR x MET bispecific antibody

gamma secretase inhibitor 1 drug

HDAC inhibitor 1 drug

  • HG146HitGenPhase 2oral1 studyHDAC inhibitor

KIT-directed ADC 1 drug

  • NN3201Novelty NobilityPhase 1intravenous1 studyKIT-directed ADC

MDM2 inhibitor 1 drug

multi-kinase TKI 1 drug

multi-kinase TKI with chemotherapy 1 drug

MYB mRNA degrader 1 drug

  • REM-422Remix Therapeutics (merging with Passage Bio)Phase 1/2oral1 studyMYB mRNA degrader

MYB splicing modulator 1 drug

  • RGT-61159Rgenta TherapeuticsPhase 1oral2 studiesMYB splicing modulator

Nectin-4-directed ADC 1 drug

pan-NOTCH transcription inhibitor 1 drug

  • CB-103Cellestia BiotechPhase 1/2oral2 studiespan-NOTCH transcription inhibitor

PD-1 x VEGF bispecific 1 drug

  • IvonescimabDana-Farber Cancer InstitutePhase 2intravenous1 studyPD-1 x VEGF bispecific

PSMA radioligand 1 drug

TrkA inhibitor 1 drug

  • VMD-928VM OncologyPhase 1/2oral1 studyTrkA inhibitor

TROP2-directed ADC 1 drug

VEGFR multi-kinase TKI 1 drug

VEGFR TKI 1 drug

VEGFR/MET/TAM TKI 1 drug

VEGFR2 TKI 2 drugs

  • ApatinibShanghai Ninth People's HospitalPhase 2oral1 studyVEGFR2 TKI
  • RivoceranibElevar TherapeuticsTrials stoppedoral1 studyVEGFR2 TKI